SOME: sintilimab plus chemotherapy followed by definitive local therapy for oligometastatic thoracic esophageal squamous cell carcinoma—a multicenter, prospective, open-label phase II trial | Synapse
May 15, 2026
SOME: sintilimab plus chemotherapy followed by definitive local therapy for oligometastatic thoracic esophageal squamous cell carcinoma—a multicenter, prospective, open-label phase II trial
Key Points
Key points are not available for this paper at this time.
Abstract
: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR2500108825.